Quick Links
 

CPCI Clinical Trials

Trial NameDescriptionSitesLink
alloRESISTA Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) With Non-escaped Epitope Targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)
  • Children's National Hospital
NCT04248192
ATLANTICAdoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
  • Children's National Hospital
NCT04691622
ATTACKPhase I Research Study Utilizing Allogeneic Multi Tumor-Associated Antigen-Specific T Lymphocytes to Advance the Care of Patients With High-Risk Solid Tumors
  • Children's National Hospital
NCT05238792
BMTCTN1903Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue - Auto -RESIST. BMTCTN1903
  • Children's National Hospital
NCT04975698
BrainChild-01Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors
  • Seattle Children's Hospital
NCT03500991
BrainChild-02Phase 1 Study of EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric Central Nervous System Tumors
  • Seattle Children's Hospital
NCT03638167
BrainChild-03Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
  • Seattle Children's Hospital
NCT04185038
CHEERSAdoptive Cord Blood ImmunotHerapy Using Expanded Cord Blood T Cells for EBV, CMV, BKV and Adenovirus Reactivation/Infection or ProphylaxiS
  • Children's National Hospital
NCT03594981
CRISPR_SCD001Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
  • UCSF Benioff Children's Hospitals
NCT04774536
EDIT-301A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease
  • UCSF Benioff Children's Hospitals
  • Colorado Children's Hospital
NCT04853576
ENCIT-01A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Autologous T-cells Lentivirally Transduced to Express CD171-specific Chimeric Antigen Receptors
  • Seattle Children's Hospital
NCT02311621
HGB 206A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease
  • UCSF Benioff Children's Hospitals
NCT02140554
MeDCaPMesenchymal Stromal Cells Delivery Through Cardiopulmonary Bypass in Pediatric Cardiac Surgery (MeDCaP)
  • Children's National Hospital
NCT04236479
NATSNovel Antigens Targeted by ex Vivo Expanded T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation
  • Children's National Hospital
NCT03180216
PLAT-05Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
  • Children's Hospital Los Angeles
  • Children's National Hospital
  • Seattle Children's Hospital
NCT03330691
PLAT-07A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
  • Children's Hospital Los Angeles
  • Seattle Children's Hospital
NCT04571138
PLAT-08Pediatric And Young Adult Leukemia Adoptive Therapy (PLAT)-08: A Phase 1 Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
  • Seattle Children's Hospital
NCT05105152
ReMINDPhase I REsearch on Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (ReMIND)
  • Children's National Hospital
NCT03652545
RESISTA Phase I Study to Evaluate the Safety, Immunologic, and Virologic RESponses of HIV-Specific T-cells With Non-Escaped Epitope Targeting (HST-NEETs) as a Therapeutic Strategy in HIV-Infected Individuals on Antiretroviral Therapy During Acute And Chronic Infection
  • Children's National Hospital
NCT03485963
RESOLVEMulti-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
  • Children's National Hospital
NCT02203903
RESTResearch Study Utilizing Expanded multi-antigen Specific lymphocytes for the treatment of Solid Tumors (REST)
  • Children's National Hospital
NCT02789228
STRIvE-01Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
  • Seattle Children's Hospital
NCT03618381
STRIvE-02Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
  • Seattle Children's Hospital
NCT04483778
SUSTAINPhase I Study Utilizing Tumor Associated Antigen Specific T cells (TAA-T) with PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
  • Children's National Hospital
NCT03843294
TDTA Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
  • UCSF Benioff Children's Hospitals
NCT03432364
TONIT CELL THERAPY OPPOSING NOVEL COVID-19 INFECTION IN IMMUNOCOMPROMISED PATIENTS
  • Children's National Hospital
NCT05141058
UCDPhase I/II Dose Escalation and Preliminary Efficacy of CD19 Directed CAR-T Cells Generated Using the Miltenyi CliniMACs Prodigy System (UCD19 CAR-T) in Pediatric Patients with Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL)
  • Colorado Children's Hospital
NCT04544592
ZUMA-4A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
  • Children's National Hospital
  • UCSF Benioff Children's Hospitals
 NCT02625480